MD Anderson Research Highlights for February 10, 2025

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This issue includes studies to be presented this week at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.

Read the full article here

Source: www.mdanderson.org

Categories: Oncologists1, General Medicine News

Tags: GU25,EndCancer

Tweets with this article

MD Anderson Cancer Center

MD Anderson experts will present new research at @ASCO #GU25, including an antibody-drug conjugate that is safe and effective in patients with advanced urothelial cancer. Read more: https://t.co/vsM7UMFyEI #EndCancer

World Cancer Day 2025: A symbol of personal and collective uncertainty – The Cancer Letter

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable.…

The Cancer Letter February 11, 2025

Serial CTRS Receives FDA Breakthrough Device Designation for NSCLC Prognosis

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

Oncology Nursing News February 11, 2025

How to Choose Effective SEO Keywords for Your Research Article | How to Write a Journal Article

Find 5 helpful tips about using keywords in your research article to help journals, and your article, be found more easily by researchers.

Wiley Oncology & Hematology February 11, 2025

February 2025 decisions news release

10 February 2025 The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, February 10) published advice…

The ICR February 11, 2025

Fox Chase Cancer Center Researchers Review Guidelines for Therapies Given to Melanoma Patients Before and After Initial Treatment

A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for…

OncLive.com February 11, 2025

Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

Journal of Neuro-Oncology – To evaluate the efficacy and safety of aumolertinib in treating non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis (LM) and…

Journal of Neuro-Oncology February 11, 2025

Related Articles